Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on the Safety and Effectiveness of Atogepant for Preventing Chronic Migraine in Children Aged 12 to 17

Fast replyInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a medication called Atogepant for the preventive treatment of Chronic Migraine in children and teenagers aged 12 to 17. Chronic Migraine is a condition where individuals experience frequent migraine headaches, often more than 15 days a month. The study aims to evaluate how safe and effective Atogepant is when taken daily as a tablet.

Participants in the study will be randomly assigned to receive either Atogepant or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for 12 weeks, during which participants will take the assigned tablets daily. Throughout the study, researchers will monitor any side effects and changes in the frequency of migraine days. The goal is to see if Atogepant can reduce the number of migraine days and improve the quality of life for those taking it.

By the end of the study, researchers hope to gather enough information to determine if Atogepant is a safe and effective option for preventing migraines in young people. This could potentially lead to a new treatment option for those suffering from Chronic Migraine, helping them experience fewer headaches and improve their daily lives.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, participants will be informed about the purpose and procedures of the trial. The study aims to evaluate the safety and effectiveness of atogepant for preventing chronic migraine in individuals aged 12 to 17 years.

  2. Step 2

    Initial assessment

    Participants will undergo an initial assessment to confirm eligibility. This includes verifying a history of migraine for at least six months and ensuring the participant's weight is between 44 pounds (20 kg) and 298 pounds (135 kg).

  3. Step 3

    Medication administration

    Participants will receive either atogepant or a placebo in the form of oral tablets. The medication is to be taken daily for a period of 12 weeks. The specific dosage will be provided by the study team.

  4. Step 4

    Ongoing monitoring

    Throughout the 12-week period, participants will be monitored for any changes in migraine frequency and severity. This includes tracking the number of migraine days and headache days each month.

  5. Step 5

    Quality of life assessment

    Participants will complete assessments to evaluate any changes in their quality of life and the impact of migraines on daily activities. This will be done using standardized questionnaires at the beginning and end of the study.

  6. Step 6

    Final evaluation

    At the end of the 12-week period, a final evaluation will be conducted to assess the overall effectiveness of the treatment. This includes measuring any reduction in migraine days and improvements in quality of life.

Who can join the trial?

5 criteria

  • Must be between 12 and 17 years old.
  • Must weigh at least 20 kg (44 pounds) and less than 135 kg (298 pounds).
  • Must have a history of migraine (a type of headache) with or without aura (visual or sensory disturbances) for at least 6 months.
  • Must have used at least one oral medication (either over-the-counter or prescription) for treating migraines in the past or currently.
  • Both males and females can participate.

Who cannot join the trial?

4 criteria

  • Patients who do not have chronic migraine cannot participate. Chronic migraine means having headaches on 15 or more days each month, with at least 8 of those days being migraines.
  • Patients who are not between the ages of 12 to 17 years old cannot participate.
  • Both male and female patients can participate, but if you are not in this age range, you cannot join.
  • Patients who are part of a vulnerable population may not be eligible. A vulnerable population includes groups like children, pregnant women, or those unable to give consent.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Atogepant is a medication being studied for its ability to prevent chronic migraines in young people aged 12 to 17. It is taken daily and works by blocking a specific protein in the brain that is involved in the development of migraines. The goal of using atogepant in this trial is to see if it can reduce the frequency and severity of migraine attacks in these young patients, making their lives more comfortable and less disrupted by headaches.

What is already known about the treatment

Atogepant – Atogepant is taken orally in the form of a tablet and is currently being studied for its effectiveness and safety in preventing chronic migraines in children aged 12 to 17. It is in the clinical trial phase, specifically a Phase 3 study, which means it is being tested on a larger group of people to confirm its benefits and monitor side effects. The main use of atogepant is to prevent chronic migraines, which are severe headaches that occur frequently. At the molecular level, atogepant works by blocking a specific receptor in the brain that is involved in the development of migraines, helping to reduce their frequency. It is classified as a calcitonin gene-related peptide (CGRP) receptor antagonist, a type of medication that targets the pathways involved in migraine attacks.

Investigated diseases

Chronic Migraine – Chronic migraine is a neurological condition characterized by frequent headache episodes. It involves experiencing headaches on 15 or more days per month, with at least 8 of those days having features of migraine headaches. Symptoms often include throbbing pain, sensitivity to light and sound, nausea, and sometimes visual disturbances. The condition can develop from episodic migraines, where the frequency of headaches increases over time. Factors such as stress, hormonal changes, and certain foods can trigger or worsen the condition. Chronic migraine can significantly impact daily activities and quality of life.
Trial detailsLast updated 2 Oct 2026
Age0-17PhasePhase IIITrial ID2024-513836-28-00Protocol codeM23-712Estimated enrolment420 patientsSponsorAbbVie Deutschland GmbH & Co. KG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).